<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660123</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202101-F-1</org_study_id>
    <nct_id>NCT04660123</nct_id>
  </id_info>
  <brief_title>A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication</brief_title>
  <official_title>A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the eradication rate of H. pylori infection, symptom improvement and the incidence&#xD;
      of adverse effects in patients using a bismuth colloidal pectin granules quadruple therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include three phases: screening, treatment and follow-up. Screening: Patients&#xD;
      who have been screened to meet the criteria for naval platooning will be enrolled after&#xD;
      signing an informed consent form.&#xD;
&#xD;
      Treatment: Subjects will receive 14 days of eradication treatment. With the exception of&#xD;
      colloidal bismuth pectin granules, which will be limited, proton pump inhibitors (PPI) and 2&#xD;
      antibiotics will be selected on the basis of the physician's experience.&#xD;
&#xD;
      Follow-up: Includes two visits. approximately 14 days of treatment and 28 days after the end&#xD;
      of treatment. Eradication of H. Pylori will be confirmed through urea breath test(UBT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>helicobacter pylori eradication</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>The primary end point of this study is H.pylori eradication,established by negative [13C] urea breath test 28 days after the end of eradication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptoms improvement rates</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>symptoms improvement rates Evaluation improvement rate of symptoms 2 weeks of treatment and 4 weeks after the end of treatment. Symptom improvement rate =#total score before treatment - total score after treatment#/total score before treatment x100%. Total score = frequency + severity.Frequency score is calculated by all the frequency of heartburn, reflux, abdominal pain, and flatulence, etc. Severity is accumulated by the degree of symptoms described above, which is divided to 4 degree as 0 presenting none, and 3 presenting most severe</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>14 days of treatment, and 28 days after treatment</time_frame>
    <description>Participants with Adverse Events as a Measure of Safety and Tolerability.The common side effects of the study include headache, dizziness, skin rash, other gastrointestinal disorders, pyrexia, cough and back pain.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Bismuth</condition>
  <arm_group>
    <arm_group_label>Quadruple therapy with colloidal bismuth pectin granules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colloidal bismuth pectin granules 150 mg, Selection of 2 antibiotics and 1 proton pump inhibitor based on China's fifth national consensus report on the management of H. pylori infection.All medication is taken orally, twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication</intervention_name>
    <description>Standard dose of proton pump inhibitor, bismuth , and 2 antibiotics, 14 days course.&#xD;
Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).&#xD;
Omeprazole 20mg, lansoprazole 30mg, pantoprazole 40mg, alprazole 5mg, any one of these.&#xD;
Bismuth is colloidal bismuth pellets, 150mg, 2 times/d.&#xD;
Antibiotic Program:&#xD;
Scheme 1 Amoxicillin 1000 mg, 2 times/d; Clarithromycin 500mg, 2 times per day Scheme 2 Amoxicillin 1000 mg, 2 times/d; Levofloxacin 5001 times/2 times Scheme 3 Amoxicillin 1000 mg, 2 times/d; Furazolidone 100mg, 2 times/d. Scheme 4 Amoxicillin 1000 mg, 2 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 5 Amoxicillin 1000 mg, 2 times/d; Tetracycline 500mg, 3 times/d or 4 times/d Scheme 6 Tetracycline 500mg, 3 times/d or 4 times/d; Metronidazole 400mg, 3 times/d or 4 times/d Scheme 7 Tetracycline 500mg, 3 times/d or 4 times/d; Furazolidone 100mg, 2 times/d.</description>
    <arm_group_label>Quadruple therapy with colloidal bismuth pectin granules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18~75,both gender.&#xD;
&#xD;
          2. Patients with upper gastrointestinal symptoms and with documented H.pylori infection.&#xD;
&#xD;
          3. Patients are willing to receive eradication treatment.&#xD;
&#xD;
          4. Women are eligible if they are not pregnant or nursing, and if they are of&#xD;
             childbearing potential they are required to use medically acceptable contraception for&#xD;
             the duration of the study and 30 days thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to study drugs.&#xD;
&#xD;
          2. Substantial organ impairment, severe or unstable cardiopulmonary or endocrine disease.&#xD;
&#xD;
          3. Constant use of anti-ulcer drugs ( including taking proton-pump.inhibitors(PPI) within&#xD;
             2 weeks before the [13C] urea breath test),antibiotics or bismuth complexes (more than&#xD;
             3 times /1 month before screening).&#xD;
&#xD;
          4. Patients were diagnosed with gastroduodenal ulcer and MALTlymphoma.&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Underwent upper gastrointestinal Surgery.&#xD;
&#xD;
          7. Patients with Barrett esophageal or highly atypical hyperplasia, have symptom of&#xD;
             dysphagia.&#xD;
&#xD;
          8. Evidence of bleeding or iron efficiency anemia.&#xD;
&#xD;
          9. A history of malignancy.&#xD;
&#xD;
         10. Drug or alcohol abuse history in the past 1 year.&#xD;
&#xD;
         11. Systemic use of corticosteroids, non steroidal anti-inflammatory drugs,anticoagulants,&#xD;
             platelet aggregation inhibitors (except the use of aspirin for less than 100 mg/d).&#xD;
&#xD;
         12. Patients who has psychological problem or poor compliance.&#xD;
&#xD;
         13. Enrolled in other clinical trials in the past 3 months.&#xD;
&#xD;
         14. Refuse to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

